|   
 | 
Sen. Julie A. Morrison
Filed: 3/8/2024
 
 
 | |  |  | 10300SB3414sam002 |  | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  | AMENDMENT TO SENATE BILL 3414 
 | 
| 2 |  |     AMENDMENT NO. ______. Amend Senate Bill 3414 by replacing  | 
| 3 |  | everything after the enacting clause with the following:
 | 
| 4 |  |     "Section 5. The Illinois Insurance Code is amended by  | 
| 5 |  | changing Section 356z.59 as follows:
 | 
| 6 |  |     (215 ILCS 5/356z.59) | 
| 7 |  |     Sec. 356z.59. Coverage for continuous glucose monitors.  | 
| 8 |  |     (a) A group or individual policy of accident and health  | 
| 9 |  | insurance or a managed care plan that is amended, delivered,  | 
| 10 |  | issued, or renewed before January 1, 2026 on or after January  | 
| 11 |  | 1, 2024 shall provide coverage for medically necessary  | 
| 12 |  | continuous glucose monitors for individuals who are diagnosed  | 
| 13 |  | with any form of diabetes mellitus type 1 or type 2 diabetes  | 
| 14 |  | and require insulin for the management of their diabetes. A  | 
| 15 |  | group or individual policy of accident and health insurance or  | 
| 16 |  | a managed care plan that is amended, delivered, issued, or  | 
|     | 
| |  |  | 10300SB3414sam002 | - 2 - | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  | renewed on or after January 1, 2026 shall provide coverage for  | 
| 2 |  | continuous glucose monitors, related supplies, and training in  | 
| 3 |  | the use of continuous glucose monitors for any individual if  | 
| 4 |  | the policy is in full alignment with Medicare and the  | 
| 5 |  | following requirements are met:  | 
| 6 |  |         (1) the individual is diagnosed with diabetes  | 
| 7 |  | mellitus; | 
| 8 |  |         (2) the continuous glucose monitor has been prescribed  | 
| 9 |  | by a physician licensed under the Medical Practice Act of  | 
| 10 |  | 1987 or a certified nurse practitioner or physician  | 
| 11 |  | assistant with a collaborative agreement with the  | 
| 12 |  | physician; | 
| 13 |  |         (3) the continuous glucose monitor has been prescribed  | 
| 14 |  | in accordance with the Food and Drug Administration's  | 
| 15 |  | indications for use; | 
| 16 |  |         (4) the prescriber has concluded that the individual  | 
| 17 |  | or individual's caregiver has sufficient training in using  | 
| 18 |  | the continuous glucose monitor, which may be evidenced by  | 
| 19 |  | the prescriber having prescribed a continuous glucose  | 
| 20 |  | monitor, and has attested that the patient will be  | 
| 21 |  | provided with that training; | 
| 22 |  |         (5) the individual either: | 
| 23 |  |             (A) uses insulin for treatment via one or more  | 
| 24 |  | injections or infusions of insulin per day, and only  | 
| 25 |  | one injection or infusion of one type of insulin shall  | 
| 26 |  | be sufficient utilization of insulin to qualify for a  | 
|     | 
| |  |  | 10300SB3414sam002 | - 3 - | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  | continuous glucose monitor under this Section; or | 
| 2 |  |             (B) has reported a history of problematic  | 
| 3 |  | hypoglycemia with documentation to the individual's  | 
| 4 |  | medical provider showing at least one of the  | 
| 5 |  | following: | 
| 6 |  |                 (i) recurrent hypoglycemic events  | 
| 7 |  | characterized by an altered mental or physical  | 
| 8 |  | state, despite multiple attempts to adjust  | 
| 9 |  | medications or modify the diabetes treatment plan,  | 
| 10 |  | as documented by a medical provider; or | 
| 11 |  |                 (ii) a history of at least one hypoglycemic  | 
| 12 |  | event characterized by an altered mental or  | 
| 13 |  | physical state requiring third-party assistance  | 
| 14 |  | for treatment of hypoglycemia, as documented by  | 
| 15 |  | the individual's medical provider, which may be  | 
| 16 |  | self-reported by the individual; third-party  | 
| 17 |  | assistance shall not, in any event, be deemed to  | 
| 18 |  | require that the individual had been admitted to a  | 
| 19 |  | hospital or visited an emergency department; and | 
| 20 |  |         (6) within 6 months prior to prescribing a continuous  | 
| 21 |  | glucose monitor, the medical provider prescribing the  | 
| 22 |  | continuous glucose monitor had an in-person or covered  | 
| 23 |  | telehealth visit with the individual to evaluate the  | 
| 24 |  | individual's diabetes control and has determined that the  | 
| 25 |  | criteria of paragraphs (1) through (5) are met. | 
| 26 |  |     Notwithstanding any other provision of this Section, to  | 
|     | 
| |  |  | 10300SB3414sam002 | - 4 - | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  | qualify for a continuous glucose monitor under this Section,  | 
| 2 |  | an individual is not required to have a diagnosis of  | 
| 3 |  | uncontrolled diabetes; have a history of emergency room visits  | 
| 4 |  | or hospitalizations; or show improved glycemic control. | 
| 5 |  |     All continuous glucose monitors covered under this Section  | 
| 6 |  | shall be approved for use by individuals, and the choice of  | 
| 7 |  | device shall be made based upon the individual's circumstances  | 
| 8 |  | and medical needs in consultation with the individual's  | 
| 9 |  | medical provider, subject to the terms of the policy. | 
| 10 |  |     (b) Any individual who is diagnosed with diabetes mellitus  | 
| 11 |  | and meets the requirements of this Section shall not be  | 
| 12 |  | required to obtain prior authorization for coverage for a  | 
| 13 |  | continuous glucose monitor, and coverage shall be continuous  | 
| 14 |  | once the continuous glucose monitor is prescribed. | 
| 15 |  |     (c) A group or individual policy of accident and health  | 
| 16 |  | insurance or a managed care plan that is amended, delivered,  | 
| 17 |  | issued, or renewed on or after January 1, 2026 shall not impose  | 
| 18 |  | a deductible, coinsurance, copayment, or any other  | 
| 19 |  | cost-sharing requirement on the coverage of one continuous  | 
| 20 |  | glucose monitor, as provided under this Section. The  | 
| 21 |  | provisions of this subsection do not apply to coverage under  | 
| 22 |  | this Section to the extent such coverage would disqualify a  | 
| 23 |  | high-deductible health plan from eligibility for a health  | 
| 24 |  | savings account pursuant to the federal Internal Revenue Code,  | 
| 25 |  | 26 U.S.C. 23. | 
| 26 |  | (Source: P.A. 102-1093, eff. 1-1-23; 103-154, eff. 6-30-23.)
 | 
|     | 
| |  |  | 10300SB3414sam002 | - 5 - | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  |     Section 10. The Illinois Public Aid Code is amended by  | 
| 2 |  | adding Section 5-16.8a as follows:
 | 
| 3 |  |     (305 ILCS 5/5-16.8a new) | 
| 4 |  |     Sec. 5-16.8a. Rules concerning continuous glucose monitor  | 
| 5 |  | coverage. The Department shall adopt rules to implement the  | 
| 6 |  | changes made to Section 356z.59 of the Illinois Insurance  | 
| 7 |  | Code, as applied to the medical assistance program. The rules  | 
| 8 |  | shall, at a minimum, provide that: | 
| 9 |  |         (1) the ordering provider must be a physician licensed  | 
| 10 |  | under the Medical Practice Act of 1987 or a certified  | 
| 11 |  | nurse practitioner or physician assistant with a  | 
| 12 |  | collaborative agreement with the physician; | 
| 13 |  |         (2) continuous glucose monitors are not required to  | 
| 14 |  | have an alarm when glucose levels are outside the  | 
| 15 |  | pre-determined range; the capacity to generate predictive  | 
| 16 |  | alerts in case of impending hypoglycemia; or the ability  | 
| 17 |  | to transmit real-time glu | 
|  |  | cose values and alerts to the  | 
| 18 |  | patient and designated other persons; | 
| 19 |  |         (3) the beneficiary is not required to need intensive  | 
| 20 |  | insulin therapy; | 
| 21 |  |         (4) the beneficiary is not required to have a recent  | 
| 22 |  | history of emergency room visits or hospitalizations  | 
| 23 |  | related to hypoglycemia, hyperglycemia, or ketoacidosis; | 
| 24 |  |         (5) if the beneficiary has gestational diabetes, the  | 
|     | 
| |  |  | 10300SB3414sam002 | - 6 - | LRB103 38590 RPS 70809 a | 
 | 
| 
 | 
| 1 |  | beneficiary is not required to have suboptimal glycemic  | 
| 2 |  | control that is likely to harm the beneficiary or the  | 
| 3 |  | fetus; | 
| 4 |  |         (6) if a beneficiary has diabetes mellitus and the  | 
| 5 |  | beneficiary does not meet the coverage requirements or if  | 
| 6 |  | the beneficiary is in a population in which continuous  | 
| 7 |  | glucose monitor usage has not been well-studied, requests  | 
| 8 |  | shall be reviewed, on a case-by-case basis, for medical  | 
| 9 |  | necessity and approved if appropriate; and | 
| 10 |  |         (7) the beneficiary is not required to obtain prior  | 
| 11 |  | authorization for coverage for a continuous glucose  | 
| 12 |  | monitor, and that coverage is continuous once the  | 
| 13 |  | continuous glucose monitor is prescribed.
 | 
| 14 |  |     Section 99. Effective date. This Act takes effect July 1,  | 
| 15 |  | 2024.". |